Biodegradable Electronic Implant DissolveChip Enters Clinical Trials: No Second Surgery Needed

Biodegradable Electronic Implant DissolveChip Enters Clinical Trials: No Second Surgery Needed

Professor John Rogers' team at Northwestern University today published a paper in Science reporting the completion of first-in-human trials of DissolveChip, a biodegradable electronic implant, in 12 patients. The implant monitors post-surgical wound healing and dissolves in the body after completing its function, with dissolution timing precisely controllable between 30 days and 2 years.

DissolveChip is based on silicon nanomembrane technology, with all electronic components fabricated from materials that hydrolyze in body fluids. The chip is just 200 micrometers thick, contains temperature, pH, and pressure sensors, and transmits data wirelessly to an external receiver.

Professor Rogers stated: "Traditional implants require a second surgery for removal, increasing infection risk and medical costs. DissolveChip eliminates this step—it quietly disappears after completing its mission, with degradation products being harmless substances the body can naturally metabolize."

In the first trial, DissolveChip was implanted in fracture fixation sites of orthopedic patients, providing real-time monitoring of bone healing. None of the 12 patients experienced adverse reactions, and all implants completed dissolution within their preset 90-day windows.

FDA has granted DissolveChip Breakthrough Device designation, with approval expected in the first half of 2029.